Ncardia Signs License Agreement with First Pharmaceutical Partner for Disease Modeling Patent Portfolio
October 12, 2017, COLOGNE, Germany–Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate companies gain access to key disease modeling patents from Ncardia.
Ncardia was recently formed through the merger of Axiogenesis and Pluriomics. The two companies have pioneered the development of stem cell derived cells for drug discovery and safety and in particular have advanced disease and tissue modeling applications.
The Ncardia patent portfolio consists of several granted patents in Europe, the USA and Japan. The drug screening and disease modeling technology not only involves patient iPSC cells, induction of the disease phenotype can also be achieved through genetic manipulation, mRNA or siRNA transfection or through chemical or physical induction. [Read more…]